ASX:HLSHealthcare
Healius (ASX:HLS) Valuation After FY26 Guidance Cut And Rising Pathology Labour Cost Pressures
Healius trading update puts labour costs and funding pressures in focus
Healius (ASX:HLS) has updated its FY26 guidance and flagged higher pathology labour costs following Fair Work Commission rulings, alongside no new federal funding for pathology in the recent budget.
The company expects Group Underlying EBITDA of A$259 million to A$264 million and Group Underlying EBIT of A$30 million to A$35 million. It is also pointing to staff cuts and collection centre closures across its pathology...